Tech Company Financing Transactions
EyeGate Pharmaceuticals Funding Round
Private investors participated in a $5.9 million Series D capital raise for EyeGate Pharmaceuticals. The funding round was announced by the company on 1/6/2011.
Transaction Overview
Company Name
Announced On
1/6/2011
Transaction Type
Venture Equity
Amount
$5,900,000
Round
Series D
Investors
Proceeds Purpose
The funds will be used to continue development of EGP-437 for the treatment of Dry EyeSyndrome (DES), an ocular surface irritation affecting several million men and women in theUnited States. EGP-437 is a dexamethasone derived corticosteroid solution speciallyformulated for delivery using the EyeGate® II Delivery System.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
271 Waverley Oaks Rd. 108
Waltham, MA 02452
USA
Waltham, MA 02452
USA
Phone
Website
Email Address
Not Recorded
Overview
EyeGate Pharma (NASDAQ: EYEG) is a late-stage specialty pharmaceutical and drug delivery company focused on developing and commercializing therapeutics and drug delivery mechanisms for treating diseases of the eye.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Stephen From
Chief Financial Officer
Sarah Romano
VP - Engineering
Michael Manzo
VP - Operations
Lisa Brandano
VP - R & D
Brenda Mann
Browse more venture capital transactions:
Prev: 1/5/2011: Millennial Media venture capital transaction
Next: 1/6/2011: Chiasma venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs